4QVX

Discovery of a Potent and Selective BCL-XL Inhibitor That Demonstrates Thrombocytopenia and Inhibits Tumor Growth in Vivo

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.10 Å
  • R-Value Free: 0.257 
  • R-Value Work: 0.191 
  • R-Value Observed: 0.194 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history. 


Literature

Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity.

Tao, Z.F., Hasvold, L., Wang, L., Wang, X., Petros, A.M., Park, C.H., Boghaert, E.R., Catron, N.D., Chen, J., Colman, P.M., Czabotar, P.E., Deshayes, K., Fairbrother, W.J., Flygare, J.A., Hymowitz, S.G., Jin, S., Judge, R.A., Koehler, M.F., Kovar, P.J., Lessene, G., Mitten, M.J., Ndubaku, C.O., Nimmer, P., Purkey, H.E., Oleksijew, A., Phillips, D.C., Sleebs, B.E., Smith, B.J., Smith, M.L., Tahir, S.K., Watson, K.G., Xiao, Y., Xue, J., Zhang, H., Zobel, K., Rosenberg, S.H., Tse, C., Leverson, J.D., Elmore, S.W., Souers, A.J.

(2014) ACS Med Chem Lett 5: 1088-1093

  • DOI: 10.1021/ml5001867
  • Primary Citation of Related Structures:  
    4QVX

  • PubMed Abstract: 

    • A-1155463, a highly potent and selective BCL-XL inhibitor, was discovered through nuclear magnetic resonance (NMR) fragment screening and structure-based design. This compound is substantially more potent against BCL-XL-dependent cell lines relative ...

    A-1155463, a highly potent and selective BCL-XL inhibitor, was discovered through nuclear magnetic resonance (NMR) fragment screening and structure-based design. This compound is substantially more potent against BCL-XL-dependent cell lines relative to our recently reported inhibitor, WEHI-539, while possessing none of its inherent pharmaceutical liabilities. A-1155463 caused a mechanism-based and reversible thrombocytopenia in mice and inhibited H146 small cell lung cancer xenograft tumor growth in vivo following multiple doses. A-1155463 thus represents an excellent tool molecule for studying BCL-XL biology as well as a productive lead structure for further optimization.

    Organizational Affiliation: 

    AbbVie, Inc. , 1 North Waukegan Road, North Chicago, Illinois 60064 United States.



Macromolecules
Find similar proteins by: 
(by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Bcl-2-like protein 1A, B167Homo sapiensMutation(s): 0 
Gene Names: BCL2L1, BCL2L, BCLX
Find proteins for Q07817 (Homo sapiens)
Explore Q07817 
Go to UniProtKB:  Q07817
NIH Common Fund Data Resources
PHAROS  Q07817
GTEx  ENSG00000171552
Protein Feature View
Expand
 ( Mouse scroll to zoom / Hold left click to move )
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
3CQ
Query on 3CQ
Download CCD File 
A, B
2-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl]-5-(3-{4-[3-(dimethylamino)prop-1-yn-1-yl]-2-fluorophenoxy}propyl)-1,3-thiazole-4-carboxylic acid
C35 H32 F N5 O4 S2
SOYCFODXNRVBTI-UHFFFAOYSA-N		 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
3CQKi:  0.009999999776482582   nM  Binding MOAD
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.10 Å
  • R-Value Free: 0.257 
  • R-Value Work: 0.191 
  • R-Value Observed: 0.194 
  • Space Group: C 2 2 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 73.107α = 90
b = 90.955β = 90
c = 83.736γ = 90
Software Package:
Software NamePurpose
ADSCdata collection
MOLREPphasing
BUSTER-TNTrefinement
PROCESSdata reduction
PROCESSdata scaling

Structure Validation

View Full Validation Report


View more in-depth experimental data

Entry History 

Deposition Data

  • Deposited Date: 2014-07-16 
  • Released Date: 2015-07-22 
    • Deposition Author(s): Park, C.H.

Revision History 

  • Version 1.0: 2015-07-22
    Type: Initial release
  • Version 1.1: 2017-07-26
    Changes: Refinement description, Source and taxonomy